Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014 (2014), Article ID 575417, 5 pages
http://dx.doi.org/10.1155/2014/575417
Case Report

Chlorambucil-Induced Acute Interstitial Pneumonitis

1Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA
2The Warren Alpert Medical School of Brown University, Providence, RI 02912, USA

Received 17 December 2013; Accepted 9 January 2014; Published 12 February 2014

Academic Editors: D. J. Allsup, S. Aref, M.-C. Kyrtsonis, and T. Sonoki

Copyright © 2014 Hammad Shafqat and Adam J. Olszewski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Tadmor and A. Polliack, “Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices,” Blood Reviews, vol. 26, no. 1, pp. 15–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. U. Knauf, T. Lissichkov, A. Aldaoud et al., “Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4378–4384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. H. Limper, “Chemotherapy-induced lung disease,” Clinics in Chest Medicine, vol. 25, no. 1, pp. 53–64, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. F. A. Rubio Jr., “Possible pulmonary effects of alkylating agents,” The New England Journal of Medicine, vol. 287, no. 22, pp. 1150–1151, 1972. View at Google Scholar · View at Scopus
  5. M. S. Rose, “Busulphan toxicity syndrome caused by chlorambucil,” British Medical Journal, vol. 2, no. 5963, article 123, 1975. View at Google Scholar · View at Scopus
  6. O. Refvem, “Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia,” Mount Sinai Journal of Medicine, vol. 44, no. 6, pp. 847–851, 1977. View at Google Scholar · View at Scopus
  7. S. R. Cole, T. J. Myers, and A. U. Klatsky, “Pulmonary disease with chlorambucil therapy,” Cancer, vol. 41, no. 2, pp. 455–459, 1978. View at Google Scholar · View at Scopus
  8. P. Godard, J. P. Marty, and F. B. Michel, “Interstitial pneumonia and chlorambucil,” Chest, vol. 76, no. 4, pp. 471–473, 1979. View at Google Scholar · View at Scopus
  9. S. D. Lane, E. C. Besa, G. Justh, and R. R. Joseph, “Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocytic leukemia,” Cancer, vol. 47, no. 1, pp. 32–36, 1981. View at Google Scholar · View at Scopus
  10. M. E. Carr Jr., “Chlorambucil induced pulmonary fibrosis: report of a case and review,” Virginia Medical, vol. 113, no. 11, pp. 677–680, 1986. View at Google Scholar · View at Scopus
  11. F. J. Giles, M. P. Smith, and A. H. Goldstone, “Chlorambucil lung toxicity,” Acta Haematologica, vol. 83, no. 3, pp. 156–158, 1990. View at Google Scholar · View at Scopus
  12. M. Mohr, D. Kingreen, H. Ruhl, and D. Huhn, “Interstitial lung disease—an underdiagnosed side effect of chlorambucil?” Annals of Hematology, vol. 67, no. 6, pp. 305–307, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Crestani, A. Jaccard, D. Israel-Biet, L.-J. Couderc, J. Frija, and J. P. Clauvel, “Chlorambucil-associated pneumonitis,” Chest, vol. 105, no. 2, pp. 634–636, 1994. View at Google Scholar · View at Scopus
  14. H. T. Khong and J. McCarthy, “Chlorambucil-induced pulmonary disease: a case report and review of the literature,” Annals of Hematology, vol. 77, no. 1-2, pp. 85–87, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Tomlinson, M. Tighe, S. A. N. Johnson, R. Stone, A. G. Nicholson, and S. Rule, “Interstitial pneumonitis following Mitozantrone, Chlorambucil and Prednisolone (MCP) chemotherapy,” Clinical Oncology, vol. 11, no. 3, pp. 184–186, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Kalambokis, D. Stefanou, E. Arkoumani, and E. Tsianos, “Bronchiolitis obliterans organizing pneumonia following chlorambucil treatment for chronic lymphocytic leukemia,” European Journal of Haematology, vol. 73, no. 2, pp. 139–142, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Catovsky, S. Richards, E. Matutes et al., “Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial,” The Lancet, vol. 370, no. 9583, pp. 230–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. B. F. Eichhorst, R. Busch, S. Stilgenbauer et al., “First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia,” Blood, vol. 114, no. 16, pp. 3382–3391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. R. Rai, B. L. Peterson, F. R. Appelbaum et al., “Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 343, no. 24, pp. 1750–1757, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Hillmen, A. B. Skotnicki, T. Robak et al., “Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 25, no. 35, pp. 5616–5623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Zucca, A. Conconi, D. Laszlo et al., “Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study,” Journal of Clinical Oncology, vol. 31, no. 5, pp. 565–572, 2013. View at Google Scholar
  22. M. Herold, A. Haas, S. Srock et al., “Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1986–1992, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. V. A. Morrison, K. R. Rai, B. L. Peterson et al., “Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011,” Journal of Clinical Oncology, vol. 19, no. 16, pp. 3611–3621, 2001. View at Google Scholar · View at Scopus
  24. J. A. Woyach, A. S. Ruppert, K. Rai et al., “Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 440–447, 2013. View at Google Scholar
  25. K. Fischer, R. Busch, A. Engelke et al., “Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with Chronic Lymphocytic Leukemia (CLL) and co-existing medical conditions (Comorbidities): final stage 2 results of the CLL11 trial,” Blood, vol. 122, no. 21, article 6, 2013. View at Google Scholar
  26. G. Raghu, H. R. Collard, J. J. Egan et al., “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. P. A. Hodnett and D. P. Naidich, “Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 2, pp. 141–149, 2013. View at Google Scholar
  28. O. Matsuno, “Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches,” Respiratory Research, vol. 13, article 39, 2012. View at Google Scholar
  29. B. Vahid and P. E. Marik, “Pulmonary complications of novel antineoplastic agents for solid tumors,” Chest, vol. 133, no. 2, pp. 528–538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. W. Malik, J. L. Myers, R. A. DeRemee, and U. Specks, “Lung toxicity associated with cyclophosphamide use: two distinct patterns,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 6, part 1, pp. 1851–1856, 1996. View at Google Scholar · View at Scopus
  31. B. Ekstrand-Hammarström, E. Wigenstam, and A. Bucht, “Inhalation of alkylating mustard causes long-term T cell-dependent inflammation in airways and growth of connective tissue,” Toxicology, vol. 280, no. 3, pp. 88–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Wigenstam, S. Jonasson, B. Koch, and A. Bucht, “Corticosteroid treatment inhibits airway hyperresponsiveness and lung injury in a murine model of chemical-induced airway inflammation,” Toxicology, vol. 301, no. 1–3, pp. 66–71, 2012. View at Google Scholar
  33. Y. Wang, P. J. Kuan, C. Xing et al., “Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer,” American Journal of Human Genetics, vol. 84, no. 1, pp. 52–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. W. E. Lawson, S. W. Grant, V. Ambrosini et al., “Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF,” Thorax, vol. 59, no. 11, pp. 977–980, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Y. Armanios, J. J.-L. Chen, J. D. Cogan et al., “Telomerase mutations in families with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 356, no. 13, pp. 1317–1326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. M. Hunninghake, H. Hatabu, Y. Okajima et al., “MUC5B promoter polymorphism and interstitial lung abnormalities,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2192–2200, 2013. View at Google Scholar